Enlivex Therapeutics Ltd.

DB:1BT Stock Report

Market Cap: €23.9m

Enlivex Therapeutics Management

Management criteria checks 1/4

Enlivex Therapeutics' CEO is Oren Hershkovitz, appointed in Nov 2019, has a tenure of 5.17 years. directly owns 0.12% of the company’s shares, worth €27.66K. The average tenure of the management team and the board of directors is 5.2 years and 2.2 years respectively.

Key information

Oren Hershkovitz

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.2yrs
CEO ownership0.1%
Management average tenure5.2yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Oren Hershkovitz's remuneration changed compared to Enlivex Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$22m

Mar 31 2024n/an/a

-US$26m

Dec 31 2023n/an/a

-US$29m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022n/an/a

-US$31m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$26m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021n/an/a

-US$14m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020n/an/a

-US$12m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$8m

Dec 31 2019US$296kUS$38k

-US$10m

Compensation vs Market: Insufficient data to establish whether Oren's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Insufficient data to compare Oren's compensation with company performance.

CEO

Oren Hershkovitz (47 yo)

5.2yrs

Tenure

US$295,600

Compensation

Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...

Leadership Team

NamePositionTenureCompensationOwnership
Shai Novik
Executive Chairman11yrsUS$536.00k3.52%
€ 839.7k
Oren Hershkovitz
Chief Executive Officer5.2yrsUS$295.60k0.12%
€ 27.7k
Dror Mevorach
Founder and Scientific Advisorno dataUS$545.00k1.1%
€ 262.9k
Shachar Shlosberger
Chief Financial Officer9yrsUS$132.00k0.0085%
€ 2.0k
Veronique Amor-Baroukh
Senior Director of Operations3yrsno datano data
Sigal Arad
Director of HR3yrsno datano data

5.2yrs

Average Tenure

52.5yo

Average Age

Experienced Management: 1BT's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Shai Novik
Executive Chairman11yrsUS$536.00k3.52%
€ 839.7k
Andrew Singer
Independent Director1.8yrsno datano data
Abraham Havron
Independent Director11yrsno data0.82%
€ 196.6k
Mitchell Levy
Clinical Advisorno datano datano data
Roger Pomerantz
Independent Vice Chairman of the Board2.7yrsno data0%
€ 0
Brian Schwartz
Director4.1yrsno data0.012%
€ 3.0k
Clifford Deutschman
Clinical Advisorno datano datano data
David Hunter
Clinical Advisor1yrno datano data
Bruno Francois
Clinical Advisor1yrno datano data
Gili Hart
Independent Director11yrsno data0.023%
€ 5.5k
Ali Mobasheri
Clinical Advisor1yrno datano data
Tobias Winkler
Clinical Advisor1yrno datano data

2.2yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 1BT's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 01:46
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enlivex Therapeutics Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Raghuram SelvarajuH.C. Wainwright & Co.